Published in Clin Exp Metastasis on October 07, 2015
Bit1 knockdown contributes to growth suppression as well as the decreases of migration and invasion abilities in esophageal squamous cell carcinoma via suppressing FAK-paxillin pathway. Mol Cancer (2016) 0.79
Daurinol blocks breast and lung cancer metastasis and development by inhibition of focal adhesion kinase (FAK). Oncotarget (2017) 0.75
The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. PLoS One (2017) 0.75
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell (2009) 13.09
Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol (2005) 11.74
Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature (1985) 9.78
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Focal adhesion kinase: the first ten years. J Cell Sci (2003) 6.83
The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer (2005) 5.57
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature (2008) 5.15
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol (2004) 4.47
Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci (2010) 3.17
Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res (2008) 3.11
Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J Cell Biol (2002) 2.84
Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol (2005) 2.75
Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci U S A (2007) 2.64
Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov (2012) 2.57
Endothelial FAK is essential for vascular network stability, cell survival, and lamellipodial formation. J Cell Biol (2006) 2.57
Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev (1998) 2.55
FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev (2003) 2.48
FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer (2014) 2.46
Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med (2007) 2.19
Focal adhesion kinase is required for blood vessel morphogenesis. Circ Res (2003) 2.18
Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol (2004) 2.12
Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells. Biochem J (2001) 1.91
Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim (2000) 1.91
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res (2007) 1.90
VEGF-induced vascular permeability is mediated by FAK. Dev Cell (2012) 1.85
Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. J Cell Biol (2008) 1.74
FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. J Cell Biol (2005) 1.70
Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol (2008) 1.69
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res (2009) 1.67
Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther (2011) 1.61
Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res (2011) 1.51
Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer (2004) 1.44
FERM control of FAK function: implications for cancer therapy. Cell Cycle (2008) 1.43
Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol Ther (2010) 1.41
Endothelial FAK is required for tumour angiogenesis. EMBO Mol Med (2010) 1.38
Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? Cancer Med (2013) 1.36
Integrin alphavbeta3, requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones (2003) 1.29
Focal adhesion kinase and tumour angiogenesis. J Pathol (2011) 1.23
VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase. Exp Cell Res (2001) 1.22
Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clin Exp Metastasis (2012) 1.20
Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J Clin Invest (2012) 1.11
Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide. Mol Cancer Ther (2012) 1.10
Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model. Cancer Biol Ther (2009) 1.09
Polyethylenimine-complexed plasmid particles targeting focal adhesion kinase function as melanoma tumor therapeutics. Mol Ther (2007) 1.08
Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene (2001) 1.08
Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function. J Cell Biol (2014) 1.07
Focal adhesion kinase regulates metastatic adhesion of carcinoma cells within liver sinusoids. Am J Pathol (2005) 1.07
Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy. Nature (2014) 1.03
Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors: implications for bone metastases. Cancer (2008) 1.00
Targeting FAK in human cancer: from finding to first clinical trials. Front Biosci (Landmark Ed) (2014) 0.99
Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton (Hoboken) (2010) 0.95
Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res (1988) 0.95
FAK-heterozygous mice display enhanced tumour angiogenesis. Nat Commun (2013) 0.92
Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res (2013) 0.92
Distinct contributions of angiogenesis and vascular co-option during the initiation of primary microtumors and micrometastases. Carcinogenesis (2011) 0.92
Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma. Oral Oncol (2012) 0.87
Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol Ther (2014) 0.87
Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines. PLoS One (2014) 0.85
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance. Oncogene (2015) 0.84
Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction. Eur J Med Chem (2014) 0.83
Aflibercept--a decoy VEGF receptor. Curr Oncol Rep (2014) 0.81
Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer. Gynecol Oncol (2014) 0.81
Ramucirumab: preclinical research and clinical development. Onco Targets Ther (2014) 0.81